Trial intelligence / Profile preview

Prolonged adjuvant capecitabine after R0 surgery for colorectal cancer with liver-only metastasis

ChiCTR-IPR-16009755Phase 4Recruiting

Sponsor
West China Hospital of Sichuan University
Start
Oct 2016
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised trial in colorectal cancer (CRC) comparing Prolonged adjuvant capecitabine with Observation (2 arms). Primary endpoint: Disease-free survival. Started Oct 2016; status: recruiting.

02

Drugs

capecitabine
03

Conditions

colorectal cancer (CRC)

Beyond the preview

Go deeper on ChiCTR-IPR-16009755.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-IPR-16009755.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call